Greenleaf Trust’s Royalty Pharma RPRX Stock Holding History

Greenleaf Trust’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-4,786	Closed	-$201K	–	736
2022 Q2	$201K	Buy	+4,786	New	+$196K	﹤0.01%	674

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SGA

Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

Greenleaf Trust's RPRX Position: Q3 2022 in Review

Greenleaf Trust sold out of Royalty Pharma (RPRX) in Q3 2022, closing a stake of 4,786 shares — an estimated $201K sold.

Greenleaf Trust first reported a position in RPRX in Q2 2022 and held it in 1 quarter. The position peaked at $201K in Q2 2022. 319 funds tracked by Wall St. Rank hold RPRX as of Q3 2022.

Greenleaf Trust reported no remaining Royalty Pharma position as of Q3 2022 after selling out during the quarter.
Greenleaf Trust sold 4,786 Royalty Pharma shares in Q3 2022, an estimated $201K.
Greenleaf Trust first reported a position in Royalty Pharma in Q2 2022 and held it in 1 quarter.
Greenleaf Trust's Royalty Pharma position peaked at $201K in Q2 2022.
319 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2022.

Based on Greenleaf Trust's 13F filing for Q3 2022, filed 10 Nov 2022.